Drug General Information
Drug ID
D09JEJ
Former ID
DNCL002399
Drug Name
CX-4945
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [523166], [542980]
Company
Cylene Pharmaceuticals
Structure
Download
2D MOL

3D MOL

Formula
C19H12ClN3O2
InChI
InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
InChIKey
MUOKSQABCJCOPU-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Casein kinase 2 Target Info Modulator [532443]
References
Ref 523166ClinicalTrials.gov (NCT01199718) Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 542980(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8126).
Ref 532443CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.